Switch theme
Sign up to access all valuation multiples
MatsukiyoCocokara & Co, formerly Matsumotokiyoshi Holdings Co., Ltd. is a large retail pharmacy in Japan. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, discount cosmetics, household items, pet supplies, groceries, and personal care products. Matsumotokiyoshi operates a private brand called matsukiyo. The highest concentration of Matsumotokiyoshi's stores are in the Kanto region, which includes Tokyo.
2007
14.6K+
LTM Revenue $7.3B
LTM EBITDA $721M
$7.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MatsukiyoCocokara has a last 12-month revenue (LTM) of $7.3B and a last 12-month EBITDA of $721M.
In the most recent fiscal year, MatsukiyoCocokara achieved revenue of $7.0B and an EBITDA of $711M.
MatsukiyoCocokara expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MatsukiyoCocokara valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.3B | XXX | $7.0B | XXX | XXX | XXX |
| Gross Profit | $2.6B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $721M | XXX | $711M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $567M | XXX | $520M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $378M | XXX | $359M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MatsukiyoCocokara's stock price is JPY 2916 (or $20).
MatsukiyoCocokara has current market cap of JPY 1.18T (or $8.1B), and EV of JPY 1.08T (or $7.4B).
See MatsukiyoCocokara trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.4B | $8.1B | XXX | XXX | XXX | XXX | $0.93 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MatsukiyoCocokara has market cap of $8.1B and EV of $7.4B.
MatsukiyoCocokara's trades at 1.1x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate MatsukiyoCocokara's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MatsukiyoCocokara has a P/E ratio of 21.4x.
See valuation multiples for MatsukiyoCocokara and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.1B | XXX | $8.1B | XXX | XXX | XXX |
| EV (current) | $7.4B | XXX | $7.4B | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 13.1x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.4x | XXX | 23.8x | XXX | XXX | XXX |
| EV/FCF | 19.7x | XXX | 24.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMatsukiyoCocokara's last 12 month revenue growth is 3%
MatsukiyoCocokara's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
MatsukiyoCocokara's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MatsukiyoCocokara's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MatsukiyoCocokara and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MatsukiyoCocokara acquired XXX companies to date.
Last acquisition by MatsukiyoCocokara was XXXXXXXX, XXXXX XXXXX XXXXXX . MatsukiyoCocokara acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MatsukiyoCocokara founded? | MatsukiyoCocokara was founded in 2007. |
| Where is MatsukiyoCocokara headquartered? | MatsukiyoCocokara is headquartered in Japan. |
| How many employees does MatsukiyoCocokara have? | As of today, MatsukiyoCocokara has 14.6K+ employees. |
| Is MatsukiyoCocokara publicy listed? | Yes, MatsukiyoCocokara is a public company listed on TKS. |
| What is the stock symbol of MatsukiyoCocokara? | MatsukiyoCocokara trades under 3088 ticker. |
| When did MatsukiyoCocokara go public? | MatsukiyoCocokara went public in 2007. |
| Who are competitors of MatsukiyoCocokara? | Similar companies to MatsukiyoCocokara include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of MatsukiyoCocokara? | MatsukiyoCocokara's current market cap is $8.1B |
| What is the current revenue of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months revenue is $7.3B. |
| What is the current revenue growth of MatsukiyoCocokara? | MatsukiyoCocokara revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of MatsukiyoCocokara? | Current revenue multiple of MatsukiyoCocokara is 1.0x. |
| Is MatsukiyoCocokara profitable? | Yes, MatsukiyoCocokara is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months EBITDA is $721M. |
| What is MatsukiyoCocokara's EBITDA margin? | MatsukiyoCocokara's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of MatsukiyoCocokara? | Current EBITDA multiple of MatsukiyoCocokara is 10.3x. |
| What is the current FCF of MatsukiyoCocokara? | MatsukiyoCocokara's last 12 months FCF is $378M. |
| What is MatsukiyoCocokara's FCF margin? | MatsukiyoCocokara's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of MatsukiyoCocokara? | Current FCF multiple of MatsukiyoCocokara is 19.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
